Janssen Daalen, JM, Meinders, MJ, Giardina, F, Roes, KCB, Stunnenberg, BC, Mathur, S, Ainslie, PN, Thijssen, DHJ and Bloem, BR (2022) Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease: study rationale and protocol. BMC Neurology, 22 (1). ISSN 1471-2377

Preview

Text Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease study rationale and protocol.pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Background: Parkinson’s disease (PD) is a neurodegenerative disease, for which no disease-modifying therapies exist. Preclinical and clinical evidence suggest that hypoxia-based therapy might have short- and long-term benefits in PD. We present the contours of the first study to assess the safety, feasibility and physiological and symptomatic impact of hypoxia-based therapy in individuals with PD. Methods/Design: In 20 individuals with PD, we will investigate the safety, tolerability and short-term symptomatic efficacy of continuous and intermittent hypoxia using individual, double-blind, randomized placebo-controlled N-of-1 trials. This design allows for dose finding and for including more individualized outcomes, as each individual serves as its own control. A wide range of exploratory outcomes is deployed, including the Movement Disorders Society Unified Parkinson’s Disease Rating scale (MDS-UPDRS) part III, Timed Up & Go Test, Mini Balance Evaluation Systems (MiniBES) test and wrist accelerometry. Also, self-reported impression of overall symptoms, motor and non-motor symptoms and urge to take dopaminergic medication will be assessed on a 10-point Likert scale. As part of a hypothesis-generating part of the study, we also deploy several exploratory outcomes to probe possible underlying mechanisms of action, including cortisol, erythropoietin and platelet-derived growth factor β. Efficacy will be assessed primarily by a Bayesian analysis. Discussion: This evaluation of hypoxia therapy could provide insight in novel pathways that may be pursued for PD treatment. This trial also serves as a proof of concept for deploying an N-of-1 design and for including individualized outcomes in PD research, as a basis for personalized treatment approaches. Trial registration: ClinicalTrials.gov Identifier: NCT05214287 (registered January 28, 2022).

Item Type:	Article
Uncontrolled Keywords:	Clinical trial; Disease-modifying; Hypoxia; Mitochondrial dysfunction; Parkinson’s disease; Treatment; Neurology & Neurosurgery; 1109 Neurosciences; 1702 Cognitive Sciences
Subjects:	R Medicine > R Medicine (General) R Medicine > RM Therapeutics. Pharmacology
Divisions:	Sport & Exercise Sciences
Publisher:	BioMed Central
SWORD Depositor:	A Symplectic
Date Deposited:	29 Jul 2022 14:21
Last Modified:	29 Jul 2022 14:30
DOI or ID number:	10.1186/s12883-022-02770-7
URI:	https://researchonline.ljmu.ac.uk/id/eprint/17308

View Item